Amplify Weight Loss Drug & Treatment ETF (THNR)
ARCA ARCA Primary 
Inside THNR: A Leaner Approach to Weight Loss Investing
Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a way to access this growing market.
Weight Loss ETF THNR Reweights Its Index: What's Up & Down
Weight loss pills and treatments have exploded in popularity since GLP-1 drugs hit the market. From Ozempic to Wegovy, those pills have changed the lives of countless people around the world.
Weight Loss Drug ETF (THNR) Hits New 52-Week High
Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.
Amplify Debuts New Weight Loss Drug ETF
On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.
